S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

SCLX Scilex Holding Company

0.3239

0.00 (0.00%)

Pre Market

Last Updated: 04:54:18

Delayed by 15 minutes

Holding Company Shares Rally Following Board Of Directors Commentary

A U.S. pharmaceutical holding company is stealing the show so far during the mid-week session following an announcement that the company’s board of directors has authorized...

To read the full story on AllPennyStocks.com, click here.

Scilex (NASDAQ:SCLX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Scilex Charts.

Scilex (NASDAQ:SCLX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Scilex Charts.

Scilex Holding Company News

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
Friday 31 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication
Wednesday 22 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
Tuesday 21 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
Tuesday 21 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
Tuesday 21 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication
Tuesday 21 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024
Tuesday 21 January 2025 (1 month ago) • GlobeNewswire Inc.

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
Thursday 16 January 2025 (2 months ago) • GlobeNewswire Inc.

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch
Monday 13 January 2025 (2 months ago) • GlobeNewswire Inc.

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Wednesday 8 January 2025 (2 months ago) • GlobeNewswire Inc.

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 t
Monday 30 December 2024 (2 months ago) • GlobeNewswire Inc.

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Monday 16 December 2024 (3 months ago) • GlobeNewswire Inc.

More Scilex Holding Company News Articles

Tonix Pharmaceuticals

Mullen Automotive

Accredited Solutions (PK)

RespireRx Pharmaceuticals (CE)

TPT Global Tech (PK)

Kraig Biocraft Laborator... (QB)

Impact Fusion (PK)

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions